Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $16.89 as of May 14th. TEVA’s forward P/E is 6.47 according to Yahoo Finance. Teva Pharmaceuticals, the world’s largest ...

Teva’s betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management’s $700 million cost-cutting plan is on track, aiming for a 30% operating margin by ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the hybrid generics and innovative medicines giant. As part of a new bid ...

Q1 adjusted EPS was $0.52, beating $0.48 estimates; Teva raised 2025 EPS outlook to $2.45–$2.65. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings—Live With Chris Capre on Wednesday ...

This week, Teva launched its most ambitious global campaign in years, ‘For Playground Earth,’ a fully integrated marketing push that reaffirms its heritage in outdoor adventure while inviting ...

Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and ...

SOPA Images / Contributor / Getty Images Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders.

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products," said Teva CEO. Teva Pharmaceutical ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands among Wednesday’s worst-performing stocks. The stock market declined on Wednesday ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping it will become a blockbuster drug - or one that generates annual sales ...

Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well ...